Further research into the precise molecular mechanisms by which FcRL1 influences BCR signaling and the potential implications of FcRL1 dysfunction in autoimmune disorders and B-cell malignancies may pave the way for developing targeted therapies that modulate B-cell responses in disease states. The gene discussed is FCRL1; the disease is autoimmune disease.